Analysts expect Jaguar Health Inc (NASDAQ:JAGX) to announce ($5.61) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Jaguar Health’s earnings, with estimates ranging from ($5.92) to ($5.29). Jaguar Health posted earnings of ($53.15) per share in the same quarter last year, which suggests a positive year over year growth rate of 89.4%. The company is scheduled to report its next earnings report on Monday, August 12th.
On average, analysts expect that Jaguar Health will report full year earnings of ($6.07) per share for the current year, with EPS estimates ranging from ($6.23) to ($5.90). For the next fiscal year, analysts anticipate that the company will report earnings of $0.03 per share, with EPS estimates ranging from $0.00 to $0.05. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Jaguar Health.
Jaguar Health (NASDAQ:JAGX) last announced its quarterly earnings data on Tuesday, May 21st. The biotechnology company reported ($12.59) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($13.29) by $0.70. Jaguar Health had a negative return on equity of 372.84% and a negative net margin of 667.59%. The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $2.20 million.
In other news, Director James J. Bochnowski bought 180,582 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were bought at an average cost of $2.00 per share, for a total transaction of $361,164.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.81% of the stock is currently owned by insiders.
Shares of Jaguar Health stock traded down $0.06 during trading hours on Tuesday, hitting $1.54. The company’s stock had a trading volume of 647,291 shares, compared to its average volume of 538,877. The stock has a 50 day moving average price of $3.02. Jaguar Health has a 12-month low of $1.48 and a 12-month high of $175.00. The company has a quick ratio of 0.18, a current ratio of 0.30 and a debt-to-equity ratio of 0.02.
Jaguar Health Company Profile
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Recommended Story: Diversification in Your Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.